# NCT05722015 (NCT05722015)

> A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05722015
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Metastatic Non-small Cell Lung Cancer
- Interventions: Pembrolizumab Formulated with Berahyaluronidase Alfa; Pemetrexed; Cisplatin; Carboplatin; Paclitaxel; Nab-paclitaxel; Pembrolizumab; Filgrastim; Pegylated filgrastim
- Enrollment: 377
- Primary outcome: Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose
- Primary outcome: Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6
- YouTube: 1
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05722015

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05722015", "email": "<work email>"}; the inbox owner confirms by the emailed link.